| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/09/2009 | EP2098500A1 Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain |
| 09/09/2009 | EP2098250A1 Orally disintegrating solid preparation |
| 09/09/2009 | EP2098249A1 Nicorandil carriers with enhanced stability |
| 09/09/2009 | EP2098248A1 Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases |
| 09/09/2009 | EP2098247A2 Prevention and treatment of androgen-deprivation induced loss of BMD or bone fractures |
| 09/09/2009 | EP2098241A1 Method for preventative treatment of health problems in calving cows |
| 09/09/2009 | EP2098238A1 Helicobacter pylori growth inhibitor containing -n-acetylglucosaminyl-binding monosaccharide derivative |
| 09/09/2009 | EP2098237A1 Analgesic agent comprising cyclic phosphatidic acid derivative |
| 09/09/2009 | EP2098236A1 Cytostatic compositions |
| 09/09/2009 | EP2098235A1 Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation |
| 09/09/2009 | EP2098234A1 Skin adhesive preparation comprising stabilized donepezil |
| 09/09/2009 | EP2098233A1 Skin adhesive preparation comprising stabilized donepezil |
| 09/09/2009 | EP2098232A1 Percutaneous absorption preparation |
| 09/09/2009 | EP2098231A1 Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| 09/09/2009 | EP2098230A1 Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis |
| 09/09/2009 | EP2098229A1 Nerve regeneration agent |
| 09/09/2009 | EP2098228A1 Antiinflammatory agent comprising 2-aminophenol or derivative thereof as active ingredient |
| 09/09/2009 | EP2098227A1 Noncarious material and anticarious agent containing rare sugar |
| 09/09/2009 | EP2098226A1 AKAP-PKA interaction inhibitors for use in the treatment of heart diseases |
| 09/09/2009 | EP2098223A1 Compressed solid dosage form |
| 09/09/2009 | EP2098222A1 Physiologically active substance-containing granular composition and method of producing the same |
| 09/09/2009 | EP2098219A1 Macrolide compositions having improved taste and stability |
| 09/09/2009 | EP2097454A2 4-1 bb ligand in inflammatory diseases |
| 09/09/2009 | EP2097453A2 Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii) |
| 09/09/2009 | EP2097440A1 Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| 09/09/2009 | EP2097437A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| 09/09/2009 | EP2097434A2 Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus |
| 09/09/2009 | EP2097423A2 Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production |
| 09/09/2009 | EP2097421A2 Carbonic anhydrase inhibitors derivatives |
| 09/09/2009 | EP2097420A1 Spiroketone acetyl-coa carboxylase inhibitors |
| 09/09/2009 | EP2097417A1 Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
| 09/09/2009 | EP2097415A1 8-ethinylxanthine derivatives as selective a2a receptor antagonists |
| 09/09/2009 | EP2097414A1 Pyrrolo [2, 3-b]pyridine derivatives as kinase modulators |
| 09/09/2009 | EP2097411A1 3 -amino-imidazo [1,2 -a]pyridine derivatives having an sglt1 and sglt2 inhibiting action, for treating type 1 and type 2 diabetes |
| 09/09/2009 | EP2097409A1 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors |
| 09/09/2009 | EP2097407A1 Pyrazole analogs |
| 09/09/2009 | EP2097406A1 Hydantoin derivatives used as mmp inhibitors |
| 09/09/2009 | EP2097404A1 Substituted dipyridyl-dihydropyrazolones and use thereof |
| 09/09/2009 | EP2097403A2 New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate |
| 09/09/2009 | EP2097402A1 Macrocyclic inhibitors of hepatitis c virus |
| 09/09/2009 | EP2097400A2 Fused substituted aminopyrrolidine derivative |
| 09/09/2009 | EP2097399A2 Novel inhibitors of chymase |
| 09/09/2009 | EP2097397A1 Tetralin analogs having sphingosine 1-phosphate agonist activity |
| 09/09/2009 | EP2097394A1 1,2,4-triazole derivatives as sigma receptor inhibitors |
| 09/09/2009 | EP2097393A1 Therapeutic g-quadruplex ligands |
| 09/09/2009 | EP2097392A1 1,2,3-triazole derivatives as sigma receptor inhibitors |
| 09/09/2009 | EP2097391A1 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
| 09/09/2009 | EP2097390A1 Amino quinazolines derivatives wuth blood platelet reducing properties |
| 09/09/2009 | EP2097389A1 Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| 09/09/2009 | EP2097388A1 Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| 09/09/2009 | EP2097386A2 Substituted dihydroimidazoles and their use in the treatment of tumors |
| 09/09/2009 | EP2097385A1 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands |
| 09/09/2009 | EP2097384A1 Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
| 09/09/2009 | EP2097381A1 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenox]-n-methylpyridine-2-carboxamide monohydrate |
| 09/09/2009 | EP2097380A1 New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| 09/09/2009 | EP2097379A1 Carboxamide derivatives as ion channel modulators |
| 09/09/2009 | EP2097378A1 Novel seh inhibitors and their use |
| 09/09/2009 | EP2097377A1 Renin inhibitors |
| 09/09/2009 | EP2097376A2 Spiro-piperidine derivatives |
| 09/09/2009 | EP2097374A2 5-alkyloxy-indolin-2-one derivatives, preparation thereof and application thereof in therapy as selective ligands of v2 vasopressin receptors |
| 09/09/2009 | EP2097373A1 Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl ) |
| 09/09/2009 | EP2097372A1 Process for the preparation of memantine and its hydrochloric acid salt form |
| 09/09/2009 | EP2097371A2 Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| 09/09/2009 | EP2097137A1 Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases. |
| 09/09/2009 | EP2097104A2 New a-beta conformer selective anti-a-beta globulomer monoclonal antibodies |
| 09/09/2009 | EP2097084A2 Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c |
| 09/09/2009 | EP2097083A2 Dosage forms and co-administration of an opioid agonist and an opioid antagonist |
| 09/09/2009 | EP2097082A1 Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis |
| 09/09/2009 | EP2097081A1 Cholesterylamines for the treatment and prevention of infectious diseases |
| 09/09/2009 | EP2097080A2 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels |
| 09/09/2009 | EP2097079A2 Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| 09/09/2009 | EP2097078A1 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| 09/09/2009 | EP2097077A1 Benzoyl peroxyde comprising compositions, at least one naphtoic acid derivative and at least one compound of polyurethane polymer-type or derivatives thereof, and their use |
| 09/09/2009 | EP2097076A1 Use of adapalene for modulating the expression of il-1ra |
| 09/09/2009 | EP2097075A1 Use of adapalene for modulating the expression of cd1d or il-10 |
| 09/09/2009 | EP2097074A2 Topical pharmaceutical composition |
| 09/09/2009 | EP2097073A1 Stable and ready-to-use oil-in-water propofol microemulsion |
| 09/09/2009 | EP2097070A1 Robust sustained release formulations of oxymorphone and methods of use thereof |
| 09/09/2009 | EP2097069A1 Robust sustained release formulations of oxymorphone |
| 09/09/2009 | EP2097067A2 A heterogeneously configured multiparticulate gastrointestinal drug delivery system |
| 09/09/2009 | EP2097063A2 Helically-shaped drug delivery system |
| 09/09/2009 | EP2096927A2 Therapeutic compositions and methods of treatment with capsianoside-type compounds |
| 09/09/2009 | EP2096924A1 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
| 09/09/2009 | EP2096919A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 09/09/2009 | EP2096917A2 Cyclopamine analogs |
| 09/09/2009 | EP2096916A2 Compounds and methods for treating estrogen receptor-related diseases |
| 09/09/2009 | EP2096915A1 Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| 09/09/2009 | EP2096912A2 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| 09/09/2009 | EP1965809B1 Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans |
| 09/09/2009 | EP1963250B1 Biphenyl derivatives as selective agonists of gamma rar receptor |
| 09/09/2009 | EP1957488B1 3-amino-2-arylpropyl azaindoles and uses thereof |
| 09/09/2009 | EP1904033B1 Method for producing pharmaceutical compositions containing glimepiride |
| 09/09/2009 | EP1902050B1 Oxazolidinone derivatives and use thereof as antibiotics |
| 09/09/2009 | EP1893197B1 Chromane substituted benzimidazole derivatives as acid pump antagonists |
| 09/09/2009 | EP1881958B1 Diacylglycerol acyltransferase inhibitors |
| 09/09/2009 | EP1876906B1 Nutritional supplement or functional food comprising oil combination |
| 09/09/2009 | EP1863433A4 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
| 09/09/2009 | EP1856045B1 1-acetic acid-indole derivatives with pgd2 antagonist activity |
| 09/09/2009 | EP1838677B1 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| 09/09/2009 | EP1833473B1 5ht2c receptor modulator compositions and methods of use |